Dixon Hughes Goodman Wealth Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$6K	Hold	61	–	–	﹤0.01%	585
2021 Q4	$7K	Buy	+61	New	+$6.65K	﹤0.01%	514

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's HZNP Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors held its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) position steady in Q1 2022 at 61 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #585.

Dixon Hughes Goodman Wealth Advisors first reported a position in HZNP in Q4 2021 and has held it in 2 quarters since. The position peaked at $7K in Q4 2021. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

Dixon Hughes Goodman Wealth Advisors held 61 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $6K as of Q1 2022.
Dixon Hughes Goodman Wealth Advisors left its Horizon Therapeutics Public Limited Company Ordinary Shares share count unchanged in Q1 2022.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #585 holding.
Dixon Hughes Goodman Wealth Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and has held it in 2 quarters since.
Dixon Hughes Goodman Wealth Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $7K in Q4 2021.
620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.